Showing results (281-290 of 617) with videos related to
Sort By:
Pageof 62
Journal of Cancer Research and Clinical Oncology|January 26, 2020
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosisPhilipp Riffel, Juliana Schwaab, Christopher Lutz, et al.The Journal of Allergy and Clinical Immunology. in Practice|September 26, 2025
Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM RegistryJohannes Lübke, Nicole Naumann, Vito Dangelo, et al.British Journal of Haematology|August 9, 2025
Midostaurin in daily clinical practice of patients with advanced systemic mastocytosisJohannes Lübke, Nicole Naumann, Timo Brand, et al.The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.Journal of Cancer Research and Clinical Oncology|September 24, 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyAndreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, et al.Scientific Reports|January 6, 2024
A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosisJohannes Lübke, Nicole Naumann, Oliver Hoffmann, et al.Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.Pageof 62